Alterations of the WNT7A Gene in Clear Cell Renal Cell Carcinomas

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Kondratov, Aleksandr G ^a   Kvasha, Sergiy M ^a   Stoliar, Liubov A ^a   Romanenko, Alina M ^b   Zgonnyk, Yury M ^b   Gordiyuk, Vasily V ^a   Kashuba, Elena V ^c,d   Rynditch, Alla V ^a   Zabarovsky, Eugene R ^c,e,f   Kashuba, Vladimir I ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^b STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^c KAROLINSKA INSTITUTE   (Sweden)

^d R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^e ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; WNT7A PROTEIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CHROMOSOME 3P; COLONY FORMATION; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; NUCLEOTIDE SEQUENCE; TUMOR SUPPRESSOR GENE; WNT7A GENE;

ADULT; AGED; AZACITIDINE; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; WNT PROTEINS; YOUNG ADULT;

EID: 84867306677     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047012     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J,Ward E (2010) Cancer statistics 2010. Cancer J Clin: 277-300.
2. Arai E, Kanai Y, (2011) Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol 4: 58-73.
3. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, et al. (2009) CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 8:31 Available: http://www.molecular-cancer.com/content/8/1/31. Accessed June 3 2009.
4. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, et al. (2010) Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 29(14): 2104-2117.
5. Glavac D, Ravnik-Glavac M, Ovcak Z, Masera A, (1996) Genetic changes in the origin and development of renal cell carcinoma (RCC). Pflugers Arch. 431: 193-4.
6. Sanz-Casla MT, Maestro ML, del Barco V, Zanna I, Moreno J,et al. (2003) Loss of heterozygosity and methylation of p16 in renal cell carcinoma. Urol Res 31: 159-162.
7. Arai E, Ushijima S, Tsuda H, Fujimoto H, Hosoda F, et al. (2008) Genetic Clustering of Clear Cell Renal Cell Carcinoma Based on-Comparative Genomic Hybridization: Its Association with DNAMethylationAlteration and Patient Outcome. Clin Cancer Res 14: 5531-5539.
8. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, et al. (2012) Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG islandmethylator phenotype clear cell renal cell carcinomas. Carcinogenesis. 2012 May 18. doi: 10.1093/carcin/bgs177.
9. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, et al. (2001) Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 61: 7277-7281.
10. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk Y, et al. (2008) Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 265: 250-257.
11. Kondratov AG, Stoliar LA, Kvasha SM, Gordiyuk VV, Zgonnyk YM, et al. (2012) Methylation pattern of the putative tumor-suppressor gene LRRC3B promoter in clear cell renal cell carcinomas. Mol Med Report 5(2): 509-512.
12. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER, (1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22(3): 200-209.
13. Skrypkina IYa, Kashuba VI, Gordiyuk VV, Saraev V, Zubko Yu, et al. (2006) Identification of changes in gene loci potentially associated with renal cancer by novel technique of NotI microarrays. Reports of NAS Ukraine: 188-192.
14. Li J, Protopopov A, Wang F, Sentchenko V, Petushkov V, et al. (2002) NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc. Natl. Acad. Sci. USA 99: 10724-10729.
15. Dunwell TL, Hesson LB, Pavlova T, Zabarovska V, Kashuba V, et al. (2009) Epigenetic analysis of childhood acute lymphoblastic leukemia. Epigenetics. 4(3): 185-193.
16. Haraldson K, Kashuba VI, Dmitriev AA, Senchenko VN, Kudryavtseva AV, et al. (2012) LRRC3B gene is frequently epigenetically inactivated in several epithelial malignancies and inhibit cell growth and replication. Biochimie 94(5): 1151-1157.
17. Law EW, Cheung AK, Kashuba VI, Pavlova TV, Zabarovsky ER, et al. (2012) Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 31(6): 728-738.
18. Senchenko VN, Anedchenko EA, Kondratieva TT, Krasnov GS, Dmitriev AA, et al. (2010) Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer. BMC Cancer 10:75. Available: http://www.biomedcentral.com/1471-2407/10/75. Accessed March 1 2010.
19. Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, et al. (2012) Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 7(5): 502-13.
20. Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, et al. (2003) WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100(18): 10429-10434.
21. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, et al. (2005) Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem. 2005 280(20): 19625-19634.
22. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, et al. (2006) Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem. 281(37): 26943-26950.
23. Tennis MA, Vanscouyk MM, Wilson LA, Kelley N, Winn RA (2012) Methylation of WNT7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. Plos One 7(3); e32921. doi:10.1371/journal.pone.0032921.
24. Tennis MA, Vanscoyk M, Freeman S, Winn RA, (2012) Promoter hypermethylation leads to loss of wnt7a in non-small cell lung cancer. Proc Am Thorac Soc 9 (2): 83-4.
25. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, et al. (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63(13): 3735-3742.
26. Kurasawa Y, Kozaki K, Pimkhaokham A, Muramatsu T, Ono H, et al. (2011) Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells. Oncogene 31(15): 1963-1974.
27. Buechling T, Boutros M, (2011) WNT signaling at and above the receptor level. Curr Top Dev Biol 97: 21-53.
28. Katoh M, (2005) WNT/PCP signaling pathway and human cancer. Oncol Rep 14(6): 1583-1588.
29. De A, (2011) WNT/Ca2+ signaling pathway: a brief overview. Acta Biochim Biophys Sin 43(10): 745-756.
30. Nelson WJ, Nusse R, (2004) Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303(5663): 1483-1487.
31. Schmidt-Ott, Kai M. Jonathan Barasch, (2008) WNT/β-catenin signaling in nephron progenitors and their epithelial progeny. Kidney Int 74(8): 1004-1008.
32. Kispert A, Vainio S, McMahon AP, (1998) Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development 125: 4225-4234.
33. Katoh M, (2003) WNT2 and human gastrointestinal cancer. Int J Mol Med. 12(5): 811-816.
34. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, et al. (2003) Wnt5a inhibits B cell and functions as a tumor suppressor in hematopoietic tissue. Cell: 349-360.
35. Ochoa-Hernandez AB, Ramos-Solano M, Meza-Canales ID, Garcia-Castro B, Rosales-Reynoso MA, et al. (2012) Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation. BMC Cancer 12: 60. Available: http://www.biomedcentral.com/1471-2407/12/60. Accessed 2012 February 7.
36. Yoshioka S, King ML, Ran S, Okuda H, Maclean JA 2nd, et al (2012) WNT7A Regulates Tumor Growth and Progression in Ovarian Cancer through the WNT/β-Catenin Pathway. Mol Cancer Res 10(3): 469-482.
37. Merritt MA, Parsons PG, Newton TR, Martyn AC, Webb PM, et al. (2009) Expression profiling identifies genes involved in neoplastic transformation of serous ovarian cancer. BMC Cancer 9:378. Available: http://www.biomedcentral.com/1471-2407/9/378. Accessed 2009 October 23.
38. Psutka SP, Eisner BH (2011) Nonradiological treatment for renal tumors. In: Mueller P, Adam A, ed(s). Interventional oncology; A practical guide for the interventional radiologist. Springer. 122 p.
39. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual. New York: Cold Spring Harbor. 181 p.
40. Alimov A, Kost-Alimova M, Liu J, Li C, Bergerheim U, et al. (2000) Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma. Oncogene 19(11): 1392-1389.
41. Wang F, Grigorieva EV, Li J, Senchenko VN, Pavlova TV, et al. (2008) HYAL1 and HYAL2 Inhibit Tumour Growth In Vivo but Not In Vitro. PLoS One. Aug 22 3(8): e3031 doi:10.1371/journal.pone.0003031.
42. Tsutomu N, Misao NI, Toshie T (2007) Effects of sulfated hyaluronan on keratinocyte differentiation and Wnt Notch gene expression. Biomaterials:844-850.
43. Spiess AN, Feig C,Ritz C (2008) accurate sigmoidal fitting of real-time PCR data by introducing a parameter for asymmetry.BMC Bioinformatics: 221-233.
44. Chenz X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, et al. (1999) Detecting Tumor-related Alterations in Plasma or Serum DNA of Patients Diagnosed with Breast Cancer. Clinical Cancer Research 5: 2297-2303.
45. Elo JP, Harkonen P, Kyllonen AP, Lukkarinen O, Poutanen M, et al. (1997) Loss of Heterozygosity at 16q24.1-q24.2. Significantly Associated with Metastatic and Aggressive Behavior of Prostate Cancer. Cancer Research 57: 3356-3359.
46. Ramburan A, Chetty R, Hadley GP, NaidooR, Govender D, (2004) Microsatellite analysis of the DCC gene in nephroblastomas: pathologic correlations and prognostic implications. Modern Pathology 17: 89-95.
47. Goessl C, Heicappell R, Munker R, Anker P, Stroun M, et al. (1998) Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res 58(20): 4728-4732.
48. Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, et al. (1998) Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 91(4): 1382-1390.
49. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, et al. (2011) RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark. 10(1): 13-26.
50. Onay H, Pehlivan S, Koyuncuoglu M, Kirkali Z, Ozkinay F, (2009) Multigene methylation analysis of conventional renal cell carcinoma. Urol Int83(1):: 107-12.
51. Hesson LB, Cooper WN, Latif F, (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26(52): 7283-301.
52. Morris MR, Ricketts CJ, Gentle D, McRonald F, Carli N, et al. (2011) Genome-wide methylation analysis identifies epigenetically inactivated tumour suppressor genes in renal cell carcinoma. Oncogene 30(12): 1390-401.
53. Zabarovsky ER, Lerman MI, Minna JD, (2002) Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. 21(45): 6915-6935.
54. Rowley H, Jones A, Spandidos D, Field J, (1996) Definition of a tumor suppressor gene locus on the short arm of chromosome 3 in squamous cell carcinoma of the head and neck by means of microsatellite markers. Arch Otolaryngol Head Neck Surg. 122(5): 497-501.
55. Calvo R, West J, Franklin W, Erickson P, Bemis L, et al. (2000) Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA. 97(23): 12776-12781.